Beta Bionics (NASDAQ:BBNX) Posts Earnings Results

Beta Bionics (NASDAQ:BBNX) issued its quarterly earnings data on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $32.12 million during the quarter. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%.

Beta Bionics Stock Performance

Shares of NASDAQ BBNX traded up $0.03 during midday trading on Tuesday, reaching $13.97. 1,474,544 shares of the company’s stock were exchanged, compared to its average volume of 1,382,766. Beta Bionics has a 52-week low of $8.89 and a 52-week high of $32.71. The business’s fifty day moving average price is $22.40 and its two-hundred day moving average price is $22.61. The stock has a market capitalization of $615.10 million and a PE ratio of -3.20.

Analyst Ratings Changes

Several research firms recently commented on BBNX. Bank of America lowered Beta Bionics from a “buy” rating to a “neutral” rating in a research note on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 29th. Stifel Nicolaus decreased their target price on shares of Beta Bionics from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Wall Street Zen lowered shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, UBS Group raised Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $26.42.

Insider Buying and Selling

In other news, insider Mike Mensinger sold 2,200 shares of the firm’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total transaction of $66,220.00. Following the completion of the sale, the insider owned 80,752 shares of the company’s stock, valued at approximately $2,430,635.20. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer directly owned 42,614 shares in the company, valued at $1,258,391.42. This represents a 31.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 32,490 shares of company stock valued at $960,835.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BBNX. GPS Wealth Strategies Group LLC lifted its stake in Beta Bionics by 45.0% during the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Beta Bionics by 0.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock worth $10,105,000 after buying an additional 931 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Beta Bionics by 3.4% in the 4th quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock worth $1,197,000 after buying an additional 1,296 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after buying an additional 1,594 shares during the last quarter. Finally, Verition Fund Management LLC grew its position in shares of Beta Bionics by 4.0% during the 3rd quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock valued at $940,000 after buying an additional 1,823 shares during the last quarter.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.